Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (GB:0REN)
LSE:0REN
0REN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
---
Bulls Say, Bears Say
Bulls Say
InnovationEdwards' innovation leadership in structural heart therapies is reinforced with the approval of SAPIEN M3, which includes both repair and replacement options for mitral and tricuspid valves.
Market ExpansionSurvey results indicate an improvement in the percentage of respondents that reported implementing measures to expand capacity for TAVR procedures, representing a positive for Edwards Lifesciences on a longer-term basis.
Product ApprovalsThe CE Mark approval of SAPIEN M3 strengthens Edwards Lifesciences’ TMTT unit, attracting more investor attention and serving as a crucial growth driver.
Bears Say
Capacity ConstraintsEW's U.S. TAVR business has been recently pressured by hospital capacity constraints.
Market CompetitionNew competitor data were somewhat disappointing relative to MDT's previously announced four-year results from this study and investor expectations heading into the conference.
Sales GrowthLatest survey results show a deceleration of Edwards Lifesciences' U.S. TAVR sales growth on an annual basis, which aligns with a more cautious outlook.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.94% Insiders
23.18%
Mutual Funds
1.51% Other Institutional Investors
49.03% Public Companies and
Individual Investors
0REN FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Currently, no data Available
What is Edwards Lifesciences’s market cap?
Currently, no data Available
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Apr 23, 2025 which is 5 days ago.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 23, 2025. The company reported CHF0.53 earnings per share for the quarter, beating the consensus estimate of CHF0.494 by CHF0.036.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.49.
How many shares outstanding does Edwards Lifesciences have?
Currently, no data Available
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of CHF0.53 in its last earnings report, beating expectations of CHF0.494. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in GB:0REN
---
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.72 (― Downside)
$65.72 (― Downside)
Blogger Sentiment
Bullish
GB:0REN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $873.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.60%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
39.43%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
---
0REN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive sentiment with strong sales growth, especially in TMTT, strategic acquisitions, and a positive outlook for future growth. Despite some challenges in TAVR growth and regional pressures, the company maintained a strong balance sheet and is optimistic about 2025.Read More>---
0REN Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
18.04% Surgical Structural Heart
6.47% Transcatheter Mitral and Tricuspid Therapies
---
0REN Stock 12 Month Forecast
Average Price Target
CHF65.72
---